Open-Label Randomized Trial of High-Dose Rifampicin to Shorten Treatment for Drug-Sensitive Pulmonary TB (Hi-Dori-3)
DOI:
https://doi.org/10.53350/Annalspakmed.1.7.7Keywords:
Rifampicin, Pyrazinamide, TB, Effectiveness, Mortality, Adverse EffectsAbstract
Objective: Aim of current study is to determine efficacy of high dose rifampicin for 3-months after culture conversion in reducing the length of treatment for drug sensitive pulmonary TB.
Study Design: Randomized Control Trial
Place and Duration: Tertiary Care Hospital of Punjab Pakistan
Methods: This study comprised of 175 patients of both genders had pulmonary disease tuberculosis were presented. Patients provided written consent for detailed demographics. Patients were treated with rifampicin 10 mg/kg, ethambutol and pyrazinamide per day for 3-months. Favorable and unfavorable outcomes among all cases were rcorded. SPSS 24.0 was used to analyze all data.
Results: Among 175 patients, 95 (54.3%) were males and 80 (45.7%) were females. We found that 50 (28.6%) patients had age 18-30 years, 75 (42.9%) were aged between 31-40 years, 30 (17.1%) had age 41-50 years and 20 (11.4%) had age >50years. 97 (55.4%) received 400mg dose per day and had BMI <25kg/m2 while 78 (44.6%) cases received 600mg/day and had BMI >25kg/m2. Thirty eight (21.7%) patients had smoking history. We found that 144 (82.4%) cases were cured. Recurrence rate was 12 (6.9%). Among all cases 23 (13.1%) patients were died during treatment. Most common adverse effects were dizziness, headache, itching and drowsiness among all cases.
Conclusion: We concluded in this study that dozes of rifampcin (400mg, 600mg) among patients of drug sensitive TB was an effective and useful with the combination of ethambutol and pyrazinamide. Frequency of cured patients were higher as compared to died patients and disease recurrence rate.
References
1. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis. 2011; 52(9):e194–9. https:// doi.org/10.1093/cid/cir184 PMID: 21467012
2 Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015; 191 (9):1058–65. https://doi.org/10.1164/rccm.201407-1264OC PMID: 25654354
3 Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007; 51(11):3781–8. https://doi.org/10.1128/AAC.01533-06 PMID: 17724157
4 World Health Organization. Guidelines for treatment of drug-sensitive tuberculosis and patient care. 2017.
5 Birch S, Govender V, Fried J, Eyles J, Daries V, Moshabela M, et al. Does treatment collection and observation each day keep the patient away? an analysis of the determinants of adherence among patients with Tuberculosis in South Africa. Health Policy Plan. 2016;31(4):454–61.
6 Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98.
7 Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371:1599–608.
8 Steingart K, Jotblad S, Robsky K, Deck D, Hopewell P, Huang D, et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2011;15(3):305–16.
9 Svensson EM, Svensson RJ, Te Brake LH, Boeree MJ, Heinrich N, Konsten S, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Clin Infect Dis. 2018;67(1):34–41.
10 Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49
11 Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, et al. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS ONE. 2019;14(3): e0213718.
12 Prasad K, Singh MB, Ryan H: Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016; 4: CD002244.
13 Marais S, Pepper DJ, Schutz C, et al.: Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. PLoS One. 2011; 6(5): e20077. PubMed Abstra
14 Organisation WH: Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. Geneva: World Health Organisation, 2017.
15 Donald PR: Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010; 90(5): 279–92.
16 WHO: Global Tuberculosis Report. Geneva: World Health Organisation, 2019.
17 Korea Disease Control and Prevention Agency. Korean Guidelines for Tuberculosis, 4th edition. 2020.
18 Van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, van Plemper Balen G, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011;52(9):e194–9.
19 Jayaram R, Gaonkar S, Kaur P, Suresh B, Mahesh B, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–24.
20 Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, et al. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations. J Infect Dis. 2018;218(6):991–9.
21 Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, et al. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS ONE. 2019;14(3): e0213718.
22 Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013; 13(1):27–35. https://doi.org/10.1016/S1473-3099(12)70264-5 PMID: 23103177
23 Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, et al. A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study. Antimicrob Agents Chemother. 2018
24 Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. J Infect Dis. 2018; 218(6):991–9. https://doi.org/10.1093/infdis/jiy242 PMID: 29718390
25 Kwak, N., Jeon, D., Park, Y. et al. Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial. Trials 23, 666 (2022). https://doi.org/10.1186/s13063-022-06631-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 M. HAMZA NOOR, ALI HAMZA MUMTAZ, MUHAMMAD FAISAL RAFIQ, HASSAN ALI, ABDUL RAHMAN, MUHAMMAD ALI HAIDER
This work is licensed under a Creative Commons Attribution 4.0 International License.
